|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001483,
umls-concept:C0007587,
umls-concept:C0007600,
umls-concept:C0086418,
umls-concept:C0205263,
umls-concept:C0238461,
umls-concept:C0678040,
umls-concept:C1412760,
umls-concept:C1419462,
umls-concept:C1518174,
umls-concept:C1709314
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-6-6
|
|
pubmed:abstractText |
Being one of the most lethal human neoplasms and refractory to such conventional treatment as chemo- and radiotherapy, anaplastic thyroid carcinoma is a prime target for innovative therapy. p53 gene inactivation is a constant feature of this neoplasia. Therefore, we evaluated a therapeutic approach based on an E1B 55-kDa gene-defective adenovirus (ONYX-015) that replicates only in cells with impaired p53 function and leads to cell death. Here we report that the ONYX-015 virus induces cell death in three human thyroid anaplastic carcinoma cell lines (ARO, FRO, and KAT-4). In addition, we found that the growth of xenograft tumors induced in athymic mice by the injection of ARO cells was drastically reduced by ONYX-015 treatment. The ONYX-015 virus worked synergistically with two antineoplastic drugs (doxorubicin and paclitaxel) in inducing ARO and KAT-4 cell death. These results suggest that ONYX-015 may be a valid tool in the treatment of the human thyroid anaplastic carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0021-972X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2525-31
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12050209-Adenocarcinoma, Follicular,
pubmed-meshheading:12050209-Adenovirus E1B Proteins,
pubmed-meshheading:12050209-Animals,
pubmed-meshheading:12050209-Antineoplastic Agents,
pubmed-meshheading:12050209-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12050209-Carcinogenicity Tests,
pubmed-meshheading:12050209-Carcinoma,
pubmed-meshheading:12050209-Carcinoma, Papillary,
pubmed-meshheading:12050209-Cell Death,
pubmed-meshheading:12050209-Defective Viruses,
pubmed-meshheading:12050209-Doxorubicin,
pubmed-meshheading:12050209-Humans,
pubmed-meshheading:12050209-Mice,
pubmed-meshheading:12050209-Mice, Nude,
pubmed-meshheading:12050209-Neoplasm Transplantation,
pubmed-meshheading:12050209-Paclitaxel,
pubmed-meshheading:12050209-Rats,
pubmed-meshheading:12050209-Thyroid Neoplasms,
pubmed-meshheading:12050209-Transplantation, Heterologous,
pubmed-meshheading:12050209-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
|
|
pubmed:affiliation |
Department of Biology and Cellular and Molecular Pathology, Faculty of Medicine and Surgery, Federico II University of Naples, via S. Pansini 5, 80131 Naples, Italy. portella@unina.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
